How is AI revolutionizing oncology data? Find out in this special 'New Frontiers' episode (aired on Bloomberg) that explores the evolution of AI-powered oncology Data Intelligence with @Larvol. #LARVOL #BloombergTV #NewFrontiers #Tech #Healthcare #Oncology #CancerResearch #Cancer #CancerData #OncologyData | @brunolarvol

🚨Breaking🚨 BeyondSpring Announces FDA Fast Track Designation for Plinabulin in Post-ICI Non-Squamous NSCLC and Strategic Transaction to Advance Global Phase 3 DUBLIN-4 Trial Toward Planned Interim Analysis beyondspringpharma.com/beyon… Learn more 👉 clin.larvol.com/trial-detail… #LARVOL #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #FDA #FDAApproval #NSCLC #LungCancer #LCSM

🚨Breaking🚨 U.S. FDA Accepts sNDA and Grants Priority Review to Bayer’s Lynkuet® (elinzanetant) for a New Indication for the Treatment of Moderate to Severe Vasomotor Symptoms Due to Endocrine Therapy Related to Breast Cancer businesswire.com/news/home/2… Learn more 👉 clin.larvol.com/trial-detail… #LARVOL #CancerResearch #CancerData #Oncology #OncologyInsights #FDA #FDAApproval #BreastCancer #BCSM #EndocrineTherapy #Lynkuet | @AnnPartridgeMD | @drsarahsam | @ErikaHamilton9 | @OncBrothers

Most-discussed trials by influencer posts on 𝕏 from IMS 2026 Explore more about oncology conferences, top trials, and reactions from oncologists: clin.larvol.com #LARVOL #IMS2026 #InternationalMyelomaSociety #Myeloma #MultipleMyeloma #MMSM #HematologicOncology #Hematology #BloodCancers #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #IMS26 | @Myeloma_Society | @RahulBanerjeeMD | @HenrychihangFu1 | @kansagraMD | @HadidiSamer | @VincentRK | @hhashmi87 | @rajshekharucms | @Mohty_EBMT | @morenodegusmao | @Abdallah81MD

Top trending companies on 𝕏 from IMS 2026 Explore more about oncology conferences, top trials, and reactions from oncologists: clin.larvol.com #LARVOL #IMS2026 #InternationalMyelomaSociety #Myeloma #MultipleMyeloma #MMSM #HematologicOncology #Hematology #BloodCancers #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #IMS26 | @Myeloma_Society | @RahulBanerjeeMD | @HenrychihangFu1 | @kansagraMD | @HadidiSamer | @VincentRK | @hhashmi87 | @rajshekharucms | @Mohty_EBMT | @morenodegusmao | @Abdallah81MD

Top trending oncologists on 𝕏 from IMS 2026 Explore more about oncology conferences, top trials, and reactions from oncologists: clin.larvol.com #LARVOL #IMS2026 #InternationalMyelomaSociety #Myeloma #MultipleMyeloma #MMSM #HematologicOncology #Hematology #BloodCancers #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #IMS26 | @Myeloma_Society | @RahulBanerjeeMD | @HenrychihangFu1 | @kansagraMD | @HadidiSamer | @VincentRK | @hhashmi87 | @rajshekharucms | @Mohty_EBMT | @morenodegusmao | @Abdallah81MD

Most-discussed trials on 𝕏 and key results from IMS 2026 Explore more about oncology conferences, top trials, and reactions from oncologists: clin.larvol.com #LARVOL #IMS2026 #InternationalMyelomaSociety #Myeloma #MultipleMyeloma #MMSM #HematologicOncology #Hematology #BloodCancers #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #IMS26 | @Myeloma_Society | @RahulBanerjeeMD | @HenrychihangFu1 | @kansagraMD | @HadidiSamer | @VincentRK | @hhashmi87 | @rajshekharucms | @Mohty_EBMT | @morenodegusmao | @Abdallah81MD

IMS 2026 - Day 3 Recap: Most Discussed Trials on 𝕏 Explore more about oncology conferences, top trials, and reactions from oncologists: clin.larvol.com #LARVOL #IMS2026 #InternationalMyelomaSociety #Myeloma #MMSM #HematologicOncology #Hematology #BloodCancers #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials | @HadidiSamer | @RahulBanerjeeMD | @VincentRK | @Abdallah81MD | @Mohty_EBMT | @Myeloma_Society

🚨Breaking🚨 Perioperative Imfinzi plus neoadjuvant enfortumab vedotin granted Priority Review in the US for patients with muscle-invasive bladder cancer astrazeneca.com/media-centre… Learn more 👉 clin.larvol.com/trial-detail… #LARVOL #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #FDA #FDAApproval #MIBC #BladderCancer #GenitourinaryCancer #GUCancer #GUCSM | @tompowles1 | @DrChoueiri | @drenriquegrande | @OncBrothers | @PGrivasMDPhD

IMS 2026 - Day 2 Recap: Most Discussed Trials on 𝕏 Explore more about oncology conferences, top trials, and reactions from oncologists: clin.larvol.com #LARVOL #IMS2026 #InternationalMyelomaSociety #Myeloma #MMSM #HematologicOncology #Hematology #BloodCancers #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials | @HadidiSamer | @RahulBanerjeeMD | @morenodegusmao | @rajshekharucms | @hhashmi87 | @Myeloma_Society

FDA approves belzutifan in combination with lenvatinib for advanced renal cell carcino... fda.gov/drugs/resources-info… clin.larvol.com/trial-detail… #LARVOL #CancerResearch #OncologyInsights #RenalCellCarcinoma #KidneyCancer #Belzutifan @DrRishabhOnco @DrChoueiri @tompowles1 @SuyogCancer

@LARVOL Oncology Podcast | Episode #46 nitter.cf/i/broadcasts/1aKbdEVBX…

Today is World Cancer Research Day. Recognizing the research, collaboration, and discoveries that continue to advance our understanding of cancer, improve treatment approaches, support better outcomes, and shape the future of oncology. #LARVOL #WorldCancerResearchDay #CancerResearch #CancerResearchDay #CancerData #Oncology #OncologyInsights #ClinicalTrials

FDA approves lirafugratinib for previously treated, unresectable, locally advanced or m... fda.gov/drugs/resources-info… clin.larvol.com/trial-detail… #LARVOL #CancerResearch #OncologyInsights #Cholangiocarcinoma #FGFR2 #TargetedTherapy @ArndtVogel @VivekSubbiah @DraMartinezLago @graokane

First-line advanced/metastatic squamous NSCLC has seen a remarkable evolution in treatment strategy. As @IASLC - WCLC 2026, brought the lung cancer community together, we looked back at several landmarks that have shaped and may continue to reshape the frontline landscape: ▶️ ⁠Platinum-doublet chemo — the historical benchmark ▶️⁠ ⁠KEYNOTE-407 (2018) — pembro + chemo established PD-1 blockade in the frontline setting ▶️ ⁠CheckMate-9LA (2020) — nivolumab + ipilimumab + limited chemo introduced a dual-checkpoint strategy ▶️⁠ ⁠HARMONi-6 (2026, interim) — ivonescimab, a PD-1×VEGF bispecific, + chemo significantly improved OS versus tislelizumab + chemotherapy in a China-based phase III study and was subsequently approved in China for first-line advanced squamous NSCLC. Across successive generations of frontline therapy, survival benchmarks have changed substantially and the mechanisms being tested have moved well beyond chemotherapy alone. Coming out of WCLC 2026, what do you think will define the next shift in 1L squamous NSCLC: better checkpoint combinations, PD-(L)1/VEGF approaches, ADCs or something else? Learn more: 🟢 KEYNOTE-407 👉 clin.larvol.com/trial-detail… 🔴 CheckMate 9LA 👉 clin.larvol.com/trial-detail… 🟡 HARMONi-6 👉 clin.larvol.com/trial-detail… Explore more insights and data from #WCLC26 👉 clin.larvol.com/conference/a… #LARVOL #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #WCLC2026 #IASLC #LungCancer #NSCLC #SCLC #LCSM #ImmunoOncology #CompetitiveIntelligence | @BalazsHalmosMD | @PatelOncology | @StephenVLiu | @ADesaiMD | @DrJNaidoo | @GlopesMd | @thenasheffect | @Alfdoc2 | @RManochakian

🚨Breaking🚨 SOTIO Advances SOT106 with Dual FDA Designations, Further Positioning the Program as a Potential Best-in-Class ADC for Sarcoma globenewswire.com/news-relea… #LARVOL #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #FDA #FDAApproval #SOT106 #ADCs #Sarcoma

CR109234 trial: Updated data from IMS 2026 2026 in 4L+ R/R MM: BsAbs landscape, adapted from Dr. Al-Ola Abdallah (@Abdallah81MD) 👉 nitter.cf/Abdallah81MD/status/19… Updated landscape 👉 clin.larvol.com/landscape/41… Learn more about CR109234 👉 clin.larvol.com/trial-detail… #LARVOL #IMS2026 #InternationalMyelomaSociety #Myeloma #MMSM #HematologicOncology #Hematology #BloodCancers #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials | @DrRakeshPopat | @mtmdphd | @RahulBanerjeeMD | @AuclairDan | @szusmani | @Myeloma_Society

NCT04751877 trial: Updated data from IMS 2026 (@Myeloma_Society) in 1L MM: anti-CD38 mAbs landscape, adapted from Dr. Akhil Santhosh (@tuttsakhil) 👉 nitter.cf/tuttsakhil/status/1880… Updated landscape 👉 clin.larvol.com/landscape/18… Learn more about NCT04751877: clin.larvol.com/trial-detail… #LARVOL #IMS2026 #InternationalMyelomaSociety #Myeloma #MMSM #HematologicOncology #Hematology #BloodCancers #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials | @mtmdphd | @szusmani | @RahulBanerjeeMD | | @End_myeloma | @VincentRK

🚨Breaking🚨 PureTech Announces Successful End-of-Phase 1 Meeting with U.S. Food and Drug Administration (FDA) and Receipt of Fast Track Designation for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplastic Syndromes (HR-MDS) businesswire.com/news/home/2… Learn more 👉clin.larvol.com/trial-detail… #LARVOL #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #ClinicalTrials #FDA #FDAApproval #MyelodysplasticSyndromes #LYT200

Today is World Gynecologic Oncology Day — recognizing awareness, research, and progress in gynecologic cancer care. #LARVOL #GynecologicOncologyDay #GynecologicOncology #Gynecology #WomensHealth #GYNSM #CancerCare #ClinicalTrials #OncologyInsights #Oncology #CancerData #CancerResearch

@LARVOL Oncology Podcast | Episode #45 nitter.cf/i/broadcasts/1qKDzWLaB…